References
- Deleuran B. W., Chu C. Q., Field M., Brennan F. M., Mitchell T., Feldmann M., et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage–pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992; 35: 1170–8
- Beckham J. C., Caldwell D. S., Peterson B. L., Pippen A. M., Currie M. S., Keefe F. J., et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor‐alpha, soluble interleukin 2‐receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D‐dimer to traditional severity and functional measures. J Clin Immunol 1992; 12: 353–61
- Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., et al. Randomised double‐blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10
- Moreland L. W., Cohen S. B., Baumgartner S. W., Tindall E. A., Bulpitt K., Martin R., et al. Long‐term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44
- Hollander J. L. Hydrocortisone and cortisone injection into arthritic joints. Comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951; 147: 1629–35
- Kirwan J. R. Systemic low‐dose glucocorticoid treatment in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 389–403
- Nikas S. N., Temekonidis T. I., Zikou A. K., Argyropoulou M. I., Efremidis S., Drosos A. A. Treatment of resistant rheumatoid arthritis by intra‐articular infliximab injections: a pilot study. Ann Rheum Dis 2004; 63: 102–3
- Bokarewa M., Tarkowski A. Local infusion of infliximab for the treatment of acute joint inflammation. Ann Rheum Dis 2003; 62: 783–4
- Schatteman L., Gyselbrecht L., De Clercq L., Mielants H. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol 2006; 33: 82–5
- Grigor C., Capell H., Stirling A., McMahon A. D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single‐blind randomised controlled trial. Lancet 2004; 364: 263–9
- Bentley G., Goodfellow J. W. Disorganisation of the knees following intra‐articular hydrocortisone injections. J Bone Joint Surg Br 1969; 51: 498–502
- Verhoeven A. C., Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997; 24: 1495–503
- Bliddal H., Qvistgaard E., Terslev L., Savnik A., Holm C. C., Kristoffersen H., et al. Injection of etanercept into arthritic joints. II: Dose–response and efficacy [abstract]. Ann Rheum Dis 2002; 61: OP0097
- Zeltser R., Valle L., Tanck C., Holyst M. M., Ritchlin C., Gaspari A. A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001; 137: 893–9
- Bliddal H., Torp‐Pedersen S. Use of small amounts of ultrasound guided air for injections. Ann Rheum Dis 2000; 59: 926–7
- Jones A., Regan M., Ledingham J., Pattrick M., Manhire A., Doherty M. Importance of placement of intra‐articular steroid injections. Br Med J 1993; 307: 1329–30
- Metz V. M., Mann F. A., Gilula L. A. Lack of correlation between site of wrist pain and location of noncommunicating defects shown by three‐compartment wrist arthrography. AJR Am J Roentgenol 1993; 160: 1239–43
- Terslev L., Torp‐Pedersen S., Qvistgaard E., Danneskiold‐Samsoe B., Bliddal H. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra‐articular treatment in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 1049–53
- Arnold E. L., Khanna D., Paulus H., Goodman M. P. Acute injection site reaction to intraarticular etanercept administration. Arthritis Rheum 2003; 48: 2078–9
- Bliddal H. Intraarticular injection of anti‐tumor necrosis factor: comment on the letter by Arnold et al. Arthritis Rheum 2004; 50: 2037–8